Click to view full size

Pfiz­er is end­ing the de­vel­op­ment of its po­ten­tial once-dai­ly pill treat­ment for obe­si­ty be­fore ven­tur­ing in­to the biggest and most ex­pen­sive lev­el of clin­i­cal test­ing.

The drug­mak­er said Tues­day that it would stop study­ing danuglipron af­ter a par­tic­i­pant in one of its tri­als ex­pe­ri­enced a pos­si­ble drug-in­duced liv­er in­jury that end­ed once the per­son stopped tak­ing the treat­ment.

The once-dai­ly ver­sion of the pill was in ear­ly-stage test­ing, with re­searchers try­ing to fig­ure out the best dose for pa­tients, a spokes­woman said. The com­pa­ny in­tend­ed to move the drug in­to late-stage test­ing, which is gen­er­al­ly the last phase of de­vel­op­ment be­fore a com­pa­ny sub­mits the po­ten­tial treat­ment to gov­ern­ment reg­u­la­tors for ap­proval.